US FDA submits interim access policy for peptide compounding to White House

US FDA: The US Food and Drug Administration is the federal agency responsible for protecting public health by regulating drugs, food, and related products, including oversight of compounding pharmacies. It has submitted an interim access policy for compounding certain peptides to the White House for review on October 15, 2026, advancing recommendations from its advisory panel on substances like BPC-157. Hims & Hers Health: Hims & Hers Health is a telehealth company that provides personalized health and wellness treatments through its platform. It has indicated plans to offer peptides if future regulations permit, positioning itself to enter this market segment as compounding rules evolve. Robert F. Kennedy Jr.: Robert F. Kennedy Jr. serves as US Secretary of Health and Human Services in the current administration. He has publicly promoted peptides for wellness uses and his department is advancing regulatory changes to facilitate compounding access. Department of Health and Human Services: The Department of Health and Human Services oversees federal health agencies including the FDA and sets national health policy. It collaborated with the FDA to submit the interim access policy for peptide compounding to the White House for consideration in October 2026. Advocacy Context: Peptides are promoted by social media influencers and HHS Secretary Robert F. Kennedy Jr. for uses including pain relief and recovery. Industry Interest: Telehealth providers like Hims & Hers Health are preparing to offer peptides pending regulatory approval. Policy Development: The US FDA and HHS submitted an interim access policy for compounding certain peptides to the White House for review.